Department of Endocrinology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, PR China.
Diabetes Res Clin Pract. 2011 Feb;91(2):195-202. doi: 10.1016/j.diabres.2010.11.012. Epub 2010 Dec 4.
To investigate the association of solute carrier family 30 member 8 (SLC30A8) rs13266634 C/T polymorphism with type 2 diabetes (T2DM), impaired glucose tolerance (IGT), and type 1 diabetes (T1DM).
We searched all the publications about the association between SLC30A8 and diabetes from PubMed, and evaluated the association between SLC30A8 rs13266634 C/T polymorphism and T2DM, IGT and T1DM, respectively, by meta-analysis of all the validated studies. Allelic and genotypic comparisons between cases and controls were evaluated.
Thirty six studies were included in the meta-analysis: 31 studies were analysed for rs13266634 C/T polymorphism with T2DM, 3 studies with IGT and 4 studies with T1DM. The pooled odds ratios (ORs) for allelic and genotypic comparisons (including additive model, co-dominant model, dominant model and recessive model) showed that rs13266634 C/T polymorphism was significantly associated with increased T2DM risk: OR=1.15, 95% confidence interval (CI)=1.13-1.17, P<0.001, P(heterogeneity)=0.041, OR=1.34, 95% CI=1.26-1.41, P<0.001, P(heterogeneity)=0.908, OR=1.20, 95% CI=1.16-1.24, P<0.001, P(heterogeneity)=0.699, and OR=1.23, 95% CI=1.17-1.30, P<0.001, P(heterogeneity)=0.801, respectively. In subgroup analyses, we found that rs13266634 C/T polymorphism was associated with T2DM risk both in Asian and European subgroup (P<0.001), but not in African (P>0.05). And the pooled odds ratio (OR) for allelic frequency comparison showed that rs13266634 C/T polymorphism was also significantly associated with IGT: OR=1.15, 95% CI=1.06-1.26, P<0.001, P(heterogeneity)=0.364. Meanwhile, our meta-analysis did not suggest that rs13266634 C/T polymorphism was associated with T1DM risk (P>0.05): OR=1.02, 95% CI=0.98-1.06, P=0.328, P(heterogeneity)=0.488 for allelic frequency comparison.
Our meta-analysis results revealed the significant association between rs13266634 C/T polymorphism and T2DM and IGT, but did not support the association between this polymorphism and T1DM.
研究溶质载体家族 30 成员 8（SLC30A8）rs13266634C/T 多态性与 2 型糖尿病（T2DM）、葡萄糖耐量受损（IGT）和 1 型糖尿病（T1DM）的相关性。
我们从 PubMed 中检索了所有关于 SLC30A8 与糖尿病相关性的出版物，并通过对所有已验证研究的荟萃分析，分别评估了 SLC30A8rs13266634C/T 多态性与 T2DM、IGT 和 T1DM 的相关性。对病例和对照组之间的等位基因和基因型比较进行了评估。
共有 36 项研究纳入荟萃分析：31 项研究分析了 rs13266634C/T 多态性与 T2DM 的关系，3 项研究分析了 IGT，4 项研究分析了 T1DM。等位基因和基因型比较（包括加性模型、共显性模型、显性模型和隐性模型）的汇总优势比（OR）表明，rs13266634C/T 多态性与 T2DM 风险增加显著相关：OR=1.15，95%置信区间（CI）=1.13-1.17，P<0.001，P（异质性）=0.041，OR=1.34，95%CI=1.26-1.41，P<0.001，P（异质性）=0.908，OR=1.20，95%CI=1.16-1.24，P<0.001，P（异质性）=0.699，OR=1.23，95%CI=1.17-1.30，P<0.001，P（异质性）=0.801，分别。亚组分析发现，rs13266634C/T 多态性与亚洲和欧洲亚组的 T2DM 风险相关（P<0.001），但与非洲亚组无关（P>0.05）。等位基因频率比较的汇总优势比（OR）表明，rs13266634C/T 多态性也与 IGT 显著相关：OR=1.15，95%CI=1.06-1.26，P<0.001，P（异质性）=0.364。同时，我们的荟萃分析并未表明 rs13266634C/T 多态性与 T1DM 风险相关（P>0.05）：OR=1.02，95%CI=0.98-1.06，P=0.328，P（异质性）=0.488，用于等位基因频率比较。
我们的荟萃分析结果表明，rs13266634C/T 多态性与 T2DM 和 IGT 显著相关，但不支持该多态性与 T1DM 相关。
